StockIQ.techHalozyme Therapeutics, Inc. (HALO) Stock Analysis
Free AI-powered analysis and research for Halozyme Therapeutics, Inc. stock
Sector: Healthcare
HALO snapshot
Data as of 3 Nov 2026 close. Updated daily.
Halozyme Therapeutics, Inc. scores 94/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 95% of its 52-week range, up 96.9% over the past year. Latest reported figures show a profit margin of 24.9%, return on equity of 173.7% and revenue growth of +47.7%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- High P/E (38.3): -10
- Strong Revenue Growth (47.7%): +8
- Excellent Profit Margin (24.9%): +10
- High Debt (15.18 D/E): -10
- Strong Liquidity (2.71 Current Ratio): +8
- Excellent ROE (173.7%): +8
- High P/B (103.98): -5
- Strong Long-term Uptrend: +8
- Strong Rise (+96.9% over 1 year): +10
- Low Volume (0.2x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full HALO report
Halozyme Therapeutics, Inc. (HALO) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze HALO Now →📰 Latest Update
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
Thu, October 29, 2026 at 1:00 PM UTC 3 min read
Halozyme Therapeutics (HALO) is set to report its earnings next week, with Wall Street anticipating significant growth. This upcoming earnings report is crucial for investors as it could provide insights into the company's financial health and future prospects, potentially influencing stock performance. Positive results may bolster investor confidence and attract new interest in the stock.